Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24188081,Ka,The CB[7] molecule forms a stable host-guest complex with triamterene (Ka = 1.69 ± 0.34 × 10(4) M(-1)) in aqueous solution (pH = 1.0).,"The delivery of triamterene by cucurbit[7]uril: synthesis, structures and pharmacokinetics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24188081/),1/[M],1.69,25642,DB00384,Triamterene
,24188081,t1/2,"Pharmacokinetic studies in rats reveal that the AUC0-∞ value of triamterene@CB[7] complex increases 2.8-fold compared with that of free triamterene, and t1/2 is prolonged from 1.42 to 2.61 h (P < 0.05) after oral administration.","The delivery of triamterene by cucurbit[7]uril: synthesis, structures and pharmacokinetics study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24188081/),h,1.42,25643,DB00384,Triamterene
,24188081,t1/2,"Pharmacokinetic studies in rats reveal that the AUC0-∞ value of triamterene@CB[7] complex increases 2.8-fold compared with that of free triamterene, and t1/2 is prolonged from 1.42 to 2.61 h (P < 0.05) after oral administration.","The delivery of triamterene by cucurbit[7]uril: synthesis, structures and pharmacokinetics study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24188081/),h,2.61,25644,DB00384,Triamterene
,8240457,systemic plasma clearance,From the obtained data the systemic plasma clearance was calculated to be 1708 ml/min.,"Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240457/),[ml] / [min],1708,43267,DB00384,Triamterene
,8240457,oral bioavailability,The oral bioavailability was calculated to be 16%.,"Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240457/),%,16,43268,DB00384,Triamterene
,8240457,fractions of,"In volunteers the fractions of the dose excreted renally were 0.5% for parent drug, 23% for the glucuronide(s) and 8% for the sulfate.","Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240457/),%,0.5,43269,DB00384,Triamterene
,8240457,fractions of,"In volunteers the fractions of the dose excreted renally were 0.5% for parent drug, 23% for the glucuronide(s) and 8% for the sulfate.","Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240457/),%,23,43270,DB00384,Triamterene
,8240457,fractions of,"In volunteers the fractions of the dose excreted renally were 0.5% for parent drug, 23% for the glucuronide(s) and 8% for the sulfate.","Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240457/),%,8,43271,DB00384,Triamterene
,6723757,lag-phase,"After a lag-phase of 33.9 +/- 5.4 min the maximum plasma concentration of furosemide was reached after 3.47 +/- 0.66 h, and the elimination half-life was approximately 2 h.",Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723757/),min,33.9,76949,DB00384,Triamterene
,6723757,elimination half-life,"After a lag-phase of 33.9 +/- 5.4 min the maximum plasma concentration of furosemide was reached after 3.47 +/- 0.66 h, and the elimination half-life was approximately 2 h.",Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723757/),h,2,76950,DB00384,Triamterene
,6723757,lag-phase,"After a lag-phase of 33.0 +/- 17.8 min the maximum plasma concentration of the main metabolite of triamterene, the OH-TA sulphuric acid ester, was reached after 1.7 +/- 0.59 h, and its elimination half-life amounted to 1.25 +/- 0.37 h.",Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723757/),min,33.0,76951,DB00384,Triamterene
,6723757,elimination half-life,"After a lag-phase of 33.0 +/- 17.8 min the maximum plasma concentration of the main metabolite of triamterene, the OH-TA sulphuric acid ester, was reached after 1.7 +/- 0.59 h, and its elimination half-life amounted to 1.25 +/- 0.37 h.",Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723757/),h,1.25,76952,DB00384,Triamterene
,6632729,bioavailability,Comparing these data with results after oral application of TA the bioavailability of TA was 52% and the extent of absorption 83%.,[Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632729/),%,52,78422,DB00384,Triamterene
,6632729,bioavailability,Comparing these data with results after oral application of TA the bioavailability of TA was 52% and the extent of absorption 83%.,[Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632729/),%,83,78423,DB00384,Triamterene
,1867656,Relative bioavailability,"Relative bioavailability of the FR and SR formulations were 82 and 41%, respectively, compared to the commercial tablet.",In vitro/in vivo evaluation of hydrochlorothiazide in experimental hydrochlorothiazide/triamterene combination tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867656/),%,82,86070,DB00384,Triamterene
,1867656,Relative bioavailability,"Relative bioavailability of the FR and SR formulations were 82 and 41%, respectively, compared to the commercial tablet.",In vitro/in vivo evaluation of hydrochlorothiazide in experimental hydrochlorothiazide/triamterene combination tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867656/),%,41,86071,DB00384,Triamterene
,3240762,elimination half-life time,The 'apparent' elimination half-life time for furosemide is 2.1h and the elimination half-life time for OH-TA-sulphate is 2.0h.,Pharmacodynamics and pharmacokinetics of furosemide-retard and furosemide-retard/triamterene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240762/),h,2.0,90729,DB00384,Triamterene
,4091871,terminal elimination half-life,RPH 2823 has a terminal elimination half-life of 3 h.,Pharmacodynamics and pharmacokinetics of the basic triamterene analogue dimethylaminohydroxypropoxytriamterene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091871/),h,3,97383,DB00384,Triamterene
,7159690,peak plasma level,"The mean peak plasma level of bemetizide after administration of the combination tablet (68.3 ng ml-1) was lower than that after administration of bemetizide alone (87.9 ng ml-1), although the times of occurrence of the peak levels were similar.",Bioavailability of bemetizide and triamterene from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159690/),[ng] / [ml],68.3,102415,DB00384,Triamterene
,7159690,peak plasma level,"The mean peak plasma level of bemetizide after administration of the combination tablet (68.3 ng ml-1) was lower than that after administration of bemetizide alone (87.9 ng ml-1), although the times of occurrence of the peak levels were similar.",Bioavailability of bemetizide and triamterene from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159690/),[ng] / [ml],87.9,102416,DB00384,Triamterene
,7159690,peak plasma level,The mean peak plasma level of triamterene after administration of the combination tablet (44.6 ng ml-1) was higher than and significantly different (p less than 0.001) from that after administration of triamterene alone (15.7 ng ml-1).,Bioavailability of bemetizide and triamterene from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159690/),[ng] / [ml],44.6,102417,DB00384,Triamterene
,7159690,peak plasma level,The mean peak plasma level of triamterene after administration of the combination tablet (44.6 ng ml-1) was higher than and significantly different (p less than 0.001) from that after administration of triamterene alone (15.7 ng ml-1).,Bioavailability of bemetizide and triamterene from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159690/),[ng] / [ml],15.7,102418,DB00384,Triamterene
less,7159690,apparent excretion,"Although bemetizide is unstable in urine, measurement of the apparent excretion of unchanged drug in the 24 h post-dose urine (less than 4 per cent of the dose) agreed with the estimate of drug bioavailability from the plasma level data.",Bioavailability of bemetizide and triamterene from a combination formulation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159690/),%,4,102419,DB00384,Triamterene
,4028626,Renal clearance,"Renal clearance of T was 314.5 +/- 121.6 ml/min, exceeding that of the metabolite, which was 206.1 +/- 93.6 ml/min.",Oral triamterene disposition. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028626/),[ml] / [min],314.5,106478,DB00384,Triamterene
,4028626,Renal clearance,"Renal clearance of T was 314.5 +/- 121.6 ml/min, exceeding that of the metabolite, which was 206.1 +/- 93.6 ml/min.",Oral triamterene disposition. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028626/),[ml] / [min],206.1,106479,DB00384,Triamterene
,2095345,F,A slight reduction in the area under the concentration-time curve (AUC) of plasma furosemide was found for the fixed combination (AUC480) F2.58 micrograms.h.ml-1; F + T 2.46 micrograms.h.ml-1; FT 1.97 micrograms.h.ml-1.,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [ml],2.58,117150,DB00384,Triamterene
,2095345,F + T,A slight reduction in the area under the concentration-time curve (AUC) of plasma furosemide was found for the fixed combination (AUC480) F2.58 micrograms.h.ml-1; F + T 2.46 micrograms.h.ml-1; FT 1.97 micrograms.h.ml-1.,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [ml],2.46,117151,DB00384,Triamterene
,2095345,FT,A slight reduction in the area under the concentration-time curve (AUC) of plasma furosemide was found for the fixed combination (AUC480) F2.58 micrograms.h.ml-1; F + T 2.46 micrograms.h.ml-1; FT 1.97 micrograms.h.ml-1.,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [ml],1.97,117152,DB00384,Triamterene
,2095345,AUC480,There was a significant reduction in the AUC480 of plasma triamterene (F + T 204.9 micrograms.h.l-1; FT 130.2 micrograms.h.l-1).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [l],204.9,117153,DB00384,Triamterene
,2095345,AUC480,There was a significant reduction in the AUC480 of plasma triamterene (F + T 204.9 micrograms.h.l-1; FT 130.2 micrograms.h.l-1).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [l],130.2,117154,DB00384,Triamterene
,2095345,F + T,There was a significant reduction in the AUC480 of plasma triamterene (F + T 204.9 micrograms.h.l-1; FT 130.2 micrograms.h.l-1).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [l],204.9,117155,DB00384,Triamterene
,2095345,FT,There was a significant reduction in the AUC480 of plasma triamterene (F + T 204.9 micrograms.h.l-1; FT 130.2 micrograms.h.l-1).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [l],130.2,117156,DB00384,Triamterene
,2095345,excretion,Sodium excretion after F + T and FT was more pronounced than after F (F + T 302 mmol; FT 311 mmol; F259 mmol).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),mM,302,117157,DB00384,Triamterene
,2095345,excretion,Sodium excretion after F + T and FT was more pronounced than after F (F + T 302 mmol; FT 311 mmol; F259 mmol).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),mM,311,117158,DB00384,Triamterene
,6831748,bioavailability,Comparing these data with results after oral application of TA the bioavailability of TA was 52% and the extent of absorption 83%.,Pharmacokinetics of triamterene. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831748/),%,52,141119,DB00384,Triamterene
,6831748,bioavailability,Comparing these data with results after oral application of TA the bioavailability of TA was 52% and the extent of absorption 83%.,Pharmacokinetics of triamterene. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831748/),%,83,141120,DB00384,Triamterene
,7166735,Unbound fractions,"Unbound fractions of triamterene and metabolite in plasma were 0.39 and 0.10 (mean of 6 subjects), respectively.",Pharmacokinetics of triamterene and its metabolite in man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7166735/),,0.39,141251,DB00384,Triamterene
,7166735,Unbound fractions,"Unbound fractions of triamterene and metabolite in plasma were 0.39 and 0.10 (mean of 6 subjects), respectively.",Pharmacokinetics of triamterene and its metabolite in man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7166735/),,0.10,141252,DB00384,Triamterene
,582410,Dialysance,4. Dialysance values of about 2 to 4 ml/min were determined for TA and OH-TA-ester.,[Pharmacokinetics of triamterene and its active metabolites in renal insufficiency (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582410/),[ml] / [min],2 to 4,151581,DB00384,Triamterene
,10379636,Cin,"Cin was significantly (P < 0.01) lower in the healthy elderly subjects [104 (12) vs 120 (14) ml x min(-2) x 1.73 m(-2) in the young], but remained within the normal range (> 90 ml x min(-2) x 1.73 m(-2)).",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[1.73·ml] / [(m)^2·(min)^2],104,181416,DB00384,Triamterene
,10379636,Cin,"Cin was significantly (P < 0.01) lower in the healthy elderly subjects [104 (12) vs 120 (14) ml x min(-2) x 1.73 m(-2) in the young], but remained within the normal range (> 90 ml x min(-2) x 1.73 m(-2)).",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[1.73·ml] / [(m)^2·(min)^2],120,181417,DB00384,Triamterene
>,10379636,Cin,"Cin was significantly (P < 0.01) lower in the healthy elderly subjects [104 (12) vs 120 (14) ml x min(-2) x 1.73 m(-2) in the young], but remained within the normal range (> 90 ml x min(-2) x 1.73 m(-2)).",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[1.73·ml] / [(m)^2·(min)^2],90,181418,DB00384,Triamterene
,10379636,C(Cr),"In contrast, C(Cr) was even lower in healthy elderly subjects [95 (24) vs 121 (20) ml x min(-1) in the young], and the Cockroft-Gault clearance underestimated true glomerular filtration rate (GFR) even more seriously [74 (17) vs 122 (16) ml min(-1)].",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[ml] / [min],95,181419,DB00384,Triamterene
,10379636,C(Cr),"In contrast, C(Cr) was even lower in healthy elderly subjects [95 (24) vs 121 (20) ml x min(-1) in the young], and the Cockroft-Gault clearance underestimated true glomerular filtration rate (GFR) even more seriously [74 (17) vs 122 (16) ml min(-1)].",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[ml] / [min],121,181420,DB00384,Triamterene
,10379636,area under the curve (AUC),"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[μg] / [h·ml],3.16,181421,DB00384,Triamterene
,10379636,area under the curve (AUC),"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),,3.01,181422,DB00384,Triamterene
,10379636,maximal plasma concentration,"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[μg] / [ml],0.42,181423,DB00384,Triamterene
,10379636,maximal plasma concentration,"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[μg] / [ml],0.44,181424,DB00384,Triamterene
,6628507,Distribution volumes of the central compartment,"Distribution volumes of the central compartment of TA and OH-TA-ester were 1.49 l/kg and 0.11 l/kg, respectively.",Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628507/),[l] / [kg],1.49,185426,DB00384,Triamterene
,6628507,Distribution volumes of the central compartment,"Distribution volumes of the central compartment of TA and OH-TA-ester were 1.49 l/kg and 0.11 l/kg, respectively.",Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628507/),[l] / [kg],0.11,185427,DB00384,Triamterene
,6628507,Terminal half-lives,Terminal half-lives were 255 min for TA and 188 min for OH-TA-ester after i.v. administration.,Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628507/),min,255,185428,DB00384,Triamterene
,6628507,Terminal half-lives,Terminal half-lives were 255 min for TA and 188 min for OH-TA-ester after i.v. administration.,Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628507/),min,188,185429,DB00384,Triamterene
,6628507,total plasma clearance,For TA total plasma clearance was 4.5 l/min and renal plasma clearance 0.22 l/kg.,Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628507/),[l] / [min],4.5,185430,DB00384,Triamterene
,6628507,renal plasma clearance,For TA total plasma clearance was 4.5 l/min and renal plasma clearance 0.22 l/kg.,Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628507/),[l] / [kg],0.22,185431,DB00384,Triamterene
,6628507,urinary recovery,"After i.v. administration the urinary recovery of TA and OH-TA-ester was 4.4% and 50.9%, respectively.",Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628507/),%,4.4,185432,DB00384,Triamterene
,6628507,urinary recovery,"After i.v. administration the urinary recovery of TA and OH-TA-ester was 4.4% and 50.9%, respectively.",Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628507/),%,50.9,185433,DB00384,Triamterene
,6628507,bioavailability,"The bioavailability of TA was 52%, corresponding to absorption of 83%.",Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628507/),%,52,185434,DB00384,Triamterene
,11132903,apparent elimination rate constant,"We found the apparent elimination rate constant oftriamterene A = 0.33 +/- 0.12 hr(-1), the apparent absorption rate constant of triamterene B = 2.68 +/- 0.55 hr(-1), the cornea-aqueous transfer coefficient in reference to the corneal volume of triamterene kc.ca = 0.28 +/- 0.05 hr(-1), the loss coefficient of triamterene from the anterior chamber ko = 0.43 +/- 0.16 hr(-1) and the amount of triamterene in the cornea at time zero Mo = 483 +/- 125 ng/ml.",Triamterene measurements in the aqueous humor of rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132903/),1/[hr],0.33,192537,DB00384,Triamterene
,11132903,apparent absorption rate constant,"We found the apparent elimination rate constant oftriamterene A = 0.33 +/- 0.12 hr(-1), the apparent absorption rate constant of triamterene B = 2.68 +/- 0.55 hr(-1), the cornea-aqueous transfer coefficient in reference to the corneal volume of triamterene kc.ca = 0.28 +/- 0.05 hr(-1), the loss coefficient of triamterene from the anterior chamber ko = 0.43 +/- 0.16 hr(-1) and the amount of triamterene in the cornea at time zero Mo = 483 +/- 125 ng/ml.",Triamterene measurements in the aqueous humor of rabbits. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132903/),1/[hr],2.68,192538,DB00384,Triamterene
,11132903,transfer coefficient,"We found the apparent elimination rate constant oftriamterene A = 0.33 +/- 0.12 hr(-1), the apparent absorption rate constant of triamterene B = 2.68 +/- 0.55 hr(-1), the cornea-aqueous transfer coefficient in reference to the corneal volume of triamterene kc.ca = 0.28 +/- 0.05 hr(-1), the loss coefficient of triamterene from the anterior chamber ko = 0.43 +/- 0.16 hr(-1) and the amount of triamterene in the cornea at time zero Mo = 483 +/- 125 ng/ml.",Triamterene measurements in the aqueous humor of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132903/),1/[hr],0.28,192539,DB00384,Triamterene
,11132903,loss coefficient,"We found the apparent elimination rate constant oftriamterene A = 0.33 +/- 0.12 hr(-1), the apparent absorption rate constant of triamterene B = 2.68 +/- 0.55 hr(-1), the cornea-aqueous transfer coefficient in reference to the corneal volume of triamterene kc.ca = 0.28 +/- 0.05 hr(-1), the loss coefficient of triamterene from the anterior chamber ko = 0.43 +/- 0.16 hr(-1) and the amount of triamterene in the cornea at time zero Mo = 483 +/- 125 ng/ml.",Triamterene measurements in the aqueous humor of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132903/),1/[hr],0.43,192540,DB00384,Triamterene
,11132903,ko,"We found the apparent elimination rate constant oftriamterene A = 0.33 +/- 0.12 hr(-1), the apparent absorption rate constant of triamterene B = 2.68 +/- 0.55 hr(-1), the cornea-aqueous transfer coefficient in reference to the corneal volume of triamterene kc.ca = 0.28 +/- 0.05 hr(-1), the loss coefficient of triamterene from the anterior chamber ko = 0.43 +/- 0.16 hr(-1) and the amount of triamterene in the cornea at time zero Mo = 483 +/- 125 ng/ml.",Triamterene measurements in the aqueous humor of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132903/),1/[hr],0.43,192541,DB00384,Triamterene
,11132903,ko,The mean of ko = 0.43 hr(-1) is significantly lower (p = 0.04% using ZTEST) than the lower limit of aqueous loss coefficient = 0.58 hr(-1) usually found in rabbits (2).,Triamterene measurements in the aqueous humor of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132903/),1/[hr],0.43,192542,DB00384,Triamterene
,11132903,aqueous loss coefficient,The mean of ko = 0.43 hr(-1) is significantly lower (p = 0.04% using ZTEST) than the lower limit of aqueous loss coefficient = 0.58 hr(-1) usually found in rabbits (2).,Triamterene measurements in the aqueous humor of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132903/),1/[hr],0.58,192543,DB00384,Triamterene
,11132903,Peak triamterene concentration,Peak triamterene concentration in the anterior chamber was P = 120 +/- 32 ng/ml.,Triamterene measurements in the aqueous humor of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132903/),[ng] / [ml],120,192544,DB00384,Triamterene
,11132903,T1/2,Half-life for elimination from the aqueous humor was T1/2 = 1.84 +/- 0.65 hr (Mean +/- SD).,Triamterene measurements in the aqueous humor of rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132903/),h,1.84,192545,DB00384,Triamterene
under,870273,peak plasma levels,"The peak plasma levels of the drug after an oral dose (200 mg) were under 0.3 microng/ml, but the concentration of the primary metabolite.",Variations in the fate of triameterene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/870273/),[μng] / [ml],0.3,194101,DB00384,Triamterene
,6736181,flow-rate,"A high-performance liquid chromatographic method has been developed for amiloride in rabbit plasma and urine which uses a reversed-phase C18 column, a mobile phase (flow-rate 2 ml/min) consisting of 32% acetonitrile in 0.15 M perchloric acid, pH 2.2, and spectrofluorometric detection via excitation at 286 nm.",High-performance liquid chromatographic analysis of amiloride in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736181/),[ml] / [min],2,215117,DB00384,Triamterene
,6736181,retention times,"Short retention times of about 2.3 and 3.8 min are observed for amiloride and the internal standard, triamterene, respectively.",High-performance liquid chromatographic analysis of amiloride in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736181/),min,2.3,215118,DB00384,Triamterene
,6736181,retention times,"Short retention times of about 2.3 and 3.8 min are observed for amiloride and the internal standard, triamterene, respectively.",High-performance liquid chromatographic analysis of amiloride in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736181/),min,3.8,215119,DB00384,Triamterene
,6891256,Peak urine elimination,Peak urine elimination of unaltered xipamide was 2.5 +/- 0.7 mg/h when given alone and 2.0 +/- 0.7 mg/h in the presence of triamterene.,[Pharmacokinetics of xipamide and triamterene in healthy probands]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891256/),[mg] / [h],2.5,260212,DB00384,Triamterene
,6891256,Peak urine elimination,Peak urine elimination of unaltered xipamide was 2.5 +/- 0.7 mg/h when given alone and 2.0 +/- 0.7 mg/h in the presence of triamterene.,[Pharmacokinetics of xipamide and triamterene in healthy probands]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891256/),[mg] / [h],2.0,260213,DB00384,Triamterene
,6891256,excretion,"The data for the triamterene excretion were 0.7 +/- 0.1 mg/h and 1.0 +/- 0.3 mg/h, respectively within 1-3 h post application.",[Pharmacokinetics of xipamide and triamterene in healthy probands]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891256/),[mg] / [h],0.7,260214,DB00384,Triamterene
,6891256,excretion,"The data for the triamterene excretion were 0.7 +/- 0.1 mg/h and 1.0 +/- 0.3 mg/h, respectively within 1-3 h post application.",[Pharmacokinetics of xipamide and triamterene in healthy probands]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891256/),[mg] / [h],1.0,260215,DB00384,Triamterene
,6891256,terminal elimination half-lives,Assuming a two-compartment pharmacokinetic model the terminal elimination half-lives of unchanged xipamide were 5.3 +/- 1.9 h (monosubstance) and 4.0 +/- 0.6 h (combination).,[Pharmacokinetics of xipamide and triamterene in healthy probands]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891256/),h,5.3,260216,DB00384,Triamterene
,6891256,terminal elimination half-lives,Assuming a two-compartment pharmacokinetic model the terminal elimination half-lives of unchanged xipamide were 5.3 +/- 1.9 h (monosubstance) and 4.0 +/- 0.6 h (combination).,[Pharmacokinetics of xipamide and triamterene in healthy probands]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891256/),h,4.0,260217,DB00384,Triamterene
